Hostname: page-component-76fb5796d-dfsvx Total loading time: 0 Render date: 2024-04-27T02:31:48.039Z Has data issue: false hasContentIssue false

The Perfect Storm: CNS Drug Development in Trouble

Published online by Cambridge University Press:  07 November 2014

Andrew A. Nierenberg*
Affiliation:
Massachusetts General Hospital, Harvard Medical School.
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Copyright
Copyright © Cambridge University Press 2010

References

REFERENCES

2.Geddes, JR, Calabrese, JR, Goodwin, GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009;194:49.CrossRefGoogle ScholarPubMed
3.Calabrese, JR, Bowden, CL, Sachs, G, et al.A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64:10131024.CrossRefGoogle ScholarPubMed
4.Bowden, CL, Grunze, H, Mullen, J, et al.A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005;66:111121.CrossRefGoogle ScholarPubMed
5.Calabrese, JR, Keck, PE, Macfadden, W, et al.A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:13511360.CrossRefGoogle ScholarPubMed
6.Thase, ME, Macfadden, W, Weisler, RH, et al.Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (The BOLDER II study). J Clin Psychopharmacol. 2006;26:600609.CrossRefGoogle Scholar